Dave Inc. CFO sells 10,459 Class A shares under 10b5-1 plan
Rhea-AI Filing Summary
Kyle Beilman, CFO/COO/Secretary of Dave Inc. (DAVE), reported sales of Class A common stock under a pre-established trading plan. On 09/12/2025 he sold 9,319 shares at a weighted average price of $230.02 and on 09/15/2025 he sold 1,140 shares at $230.00, reducing his reported direct holdings from 214,732 shares to 213,592 shares.
The filing notes the sales were executed pursuant to a Rule 10b5-1 plan adopted June 4, 2025, and the weighted average price for the 09/12/2025 sale reflects multiple executions between $230.00 and $230.45. The form is signed by an attorney-in-fact on behalf of Mr. Beilman.
Positive
- Sales executed under a Rule 10b5-1 trading plan, indicating preplanned transactions rather than opportunistic timing
- Filing includes weighted-average price and offers to disclose per-trade prices on request, supporting transparency
- Complete reporting of officer role and updated beneficial ownership counts
Negative
- None.
Insights
TL;DR: Insider sold 10,459 Class A shares via a 10b5-1 plan, a routine disclosure that modestly reduces holdings.
The transactions consist solely of open-market sales under a Rule 10b5-1 trading plan adopted June 4, 2025, with total shares sold of 10,459 at prices around $230. The filing shows reported direct holdings declining from 214,732 to 213,592 shares, indicating these were modest sales relative to disclosed holdings. No derivative activity or other changes in beneficial ownership are reported. For investors, this is a standard insider liquidity event documented under compliance procedures; the filing contains no statements of new agreements or compensatory grants.
TL;DR: Proper disclosure of 10b5-1 plan sales and weighted-average pricing demonstrates compliance with insider-trading rules.
The Form 4 clearly identifies the reporting person, officer roles, transaction dates, quantities, prices, and the existence and adoption date of the 10b5-1 plan, satisfying key disclosure requirements. The explanatory note commits to provide per-trade price details on request, which enhances transparency. There are no indications of unusual timing or undisclosed related-party arrangements within this filing.
FAQ
What shares did Kyle Beilman sell according to the Form 4 for DAVE?
At what price were the DAVE shares sold in the reported transactions?
Were the sales by Kyle Beilman part of a Rule 10b5-1 plan?
How did these transactions change Beilman's reported holdings of DAVE stock?
Who signed the Form 4 filing for Kyle Beilman?